PMID- 33392702
OWN - NLM
STAT- MEDLINE
DCOM- 20210126
LR  - 20210126
IS  - 1432-0584 (Electronic)
IS  - 0939-5555 (Linking)
VI  - 100
IP  - 2
DP  - 2021 Feb
TI  - A longitudinal analysis of chromosomal abnormalities in disease progression from 
      MGUS/SMM to newly diagnosed and relapsed multiple myeloma.
PG  - 437-443
LID - 10.1007/s00277-020-04384-w [doi]
AB  - We analyzed variations in terms of chromosomal abnormalities (CA) by fluorescence 
      in situ hybridization (FISH) analysis on purified bone marrow plasma cells 
      throughout the progression from monoclonal gammopathy of undetermined 
      significance/smoldering multiple myeloma (MGUS/SMM) to newly diagnosed MM/plasma 
      cell leukemia (NDMM/PCL) at diagnosis and from diagnostic samples to progressive 
      disease. High risk was defined by the presence of at least del(17p), t(4;14), 
      and/or t(14;16). 1p/1q detection (in the standard FISH panel from 2012 onward) 
      was not available for all patients. We analyzed 139 MM/PCL diagnostic samples 
      from 144 patients, with a median follow-up of 71 months: high-risk CA at 
      diagnosis (MGUS/SMM or NDMM) was present in 28% of samples, whereas 37-39% showed 
      high-risk CA at relapse. In 115 patients with NDMM who evolved to 
      relapsed/refractory MM, we identified 3 different populations: (1) 31/115 
      patients (27%) with gain of new CA (del13, del17p, t(4;14), t(14;16) or 1q CA 
      when available); (2) 10/115 (9%) patients with loss of a previously identified 
      CA; and (3) 74 patients with no changes. The CA gain group showed a median 
      overall survival of 66 months vs. 84 months in the third group (HR 0.56, 95% CI 
      0.34-0.92, p = 0.023). Clonal evolution occurs as disease progresses after 
      different chemotherapy lines. Patients who acquired high-risk CA had the poorest 
      prognosis. Our findings highlight the importance of performing FISH analysis both 
      at diagnosis and at relapse.
FAU - Oliva, Stefania
AU  - Oliva S
AUID- ORCID: 0000-0002-3084-180X
AD  - Myeloma Unit, Division of Hematology, University of Torino, Azienda 
      Ospedaliero-Universitaria Citta della Salute e della Scienza di Torino, via 
      Genova 3, 10126, Torino, Italy. stefania.olivamolinet@gmail.com.
FAU - De Paoli, Lorenzo
AU  - De Paoli L
AD  - Division of Hematology, Department of Translational Medicine, University of 
      Eastern Piedmont, Novara, Italy.
FAU - Ruggeri, Marina
AU  - Ruggeri M
AD  - Myeloma Unit, Division of Hematology, University of Torino, Azienda 
      Ospedaliero-Universitaria Citta della Salute e della Scienza di Torino, via 
      Genova 3, 10126, Torino, Italy.
FAU - Caltagirone, Simona
AU  - Caltagirone S
AD  - Myeloma Unit, Division of Hematology, University of Torino, Azienda 
      Ospedaliero-Universitaria Citta della Salute e della Scienza di Torino, via 
      Genova 3, 10126, Torino, Italy.
FAU - Troia, Rossella
AU  - Troia R
AD  - Myeloma Unit, Division of Hematology, University of Torino, Azienda 
      Ospedaliero-Universitaria Citta della Salute e della Scienza di Torino, via 
      Genova 3, 10126, Torino, Italy.
FAU - Oddolo, Daniela
AU  - Oddolo D
AD  - Myeloma Unit, Division of Hematology, University of Torino, Azienda 
      Ospedaliero-Universitaria Citta della Salute e della Scienza di Torino, via 
      Genova 3, 10126, Torino, Italy.
FAU - D'Agostino, Mattia
AU  - D'Agostino M
AD  - Myeloma Unit, Division of Hematology, University of Torino, Azienda 
      Ospedaliero-Universitaria Citta della Salute e della Scienza di Torino, via 
      Genova 3, 10126, Torino, Italy.
FAU - Gilestro, Milena
AU  - Gilestro M
AD  - Myeloma Unit, Division of Hematology, University of Torino, Azienda 
      Ospedaliero-Universitaria Citta della Salute e della Scienza di Torino, via 
      Genova 3, 10126, Torino, Italy.
FAU - Mina, Roberto
AU  - Mina R
AD  - Myeloma Unit, Division of Hematology, University of Torino, Azienda 
      Ospedaliero-Universitaria Citta della Salute e della Scienza di Torino, via 
      Genova 3, 10126, Torino, Italy.
FAU - Saraci, Elona
AU  - Saraci E
AD  - Myeloma Unit, Division of Hematology, University of Torino, Azienda 
      Ospedaliero-Universitaria Citta della Salute e della Scienza di Torino, via 
      Genova 3, 10126, Torino, Italy.
FAU - Margiotta Casaluci, Gloria
AU  - Margiotta Casaluci G
AD  - Division of Hematology, Department of Translational Medicine, University of 
      Eastern Piedmont, Novara, Italy.
FAU - Genuardi, Elisa
AU  - Genuardi E
AD  - Myeloma Unit, Division of Hematology, University of Torino, Azienda 
      Ospedaliero-Universitaria Citta della Salute e della Scienza di Torino, via 
      Genova 3, 10126, Torino, Italy.
FAU - Bringhen, Sara
AU  - Bringhen S
AD  - Myeloma Unit, Division of Hematology, University of Torino, Azienda 
      Ospedaliero-Universitaria Citta della Salute e della Scienza di Torino, via 
      Genova 3, 10126, Torino, Italy.
FAU - Boccadoro, Mario
AU  - Boccadoro M
AD  - Myeloma Unit, Division of Hematology, University of Torino, Azienda 
      Ospedaliero-Universitaria Citta della Salute e della Scienza di Torino, via 
      Genova 3, 10126, Torino, Italy.
FAU - Omede, Paola
AU  - Omede P
AD  - Myeloma Unit, Division of Hematology, University of Torino, Azienda 
      Ospedaliero-Universitaria Citta della Salute e della Scienza di Torino, via 
      Genova 3, 10126, Torino, Italy.
LA  - eng
PT  - Journal Article
DEP - 20210103
PL  - Germany
TA  - Ann Hematol
JT  - Annals of hematology
JID - 9107334
SB  - IM
MH  - Aged
MH  - *Chromosome Aberrations
MH  - Chromosomes, Human/*genetics
MH  - *Clonal Evolution
MH  - Disease-Free Survival
MH  - Female
MH  - Follow-Up Studies
MH  - Humans
MH  - *Leukemia, Plasma Cell/genetics/mortality
MH  - Longitudinal Studies
MH  - Male
MH  - Middle Aged
MH  - *Monoclonal Gammopathy of Undetermined Significance/genetics/mortality
MH  - Retrospective Studies
MH  - Risk Factors
MH  - *Smoldering Multiple Myeloma/genetics/mortality
MH  - Survival Rate
OTO - NOTNLM
OT  - Clonal evolution
OT  - Cytogenetic abnormalities
OT  - Disease progression
OT  - FISH
OT  - Fluorescence in situ hybridization
OT  - Multiple myeloma
EDAT- 2021/01/05 06:00
MHDA- 2021/01/27 06:00
CRDT- 2021/01/04 05:33
PHST- 2020/06/08 00:00 [received]
PHST- 2020/12/16 00:00 [accepted]
PHST- 2021/01/05 06:00 [pubmed]
PHST- 2021/01/27 06:00 [medline]
PHST- 2021/01/04 05:33 [entrez]
AID - 10.1007/s00277-020-04384-w [pii]
AID - 10.1007/s00277-020-04384-w [doi]
PST - ppublish
SO  - Ann Hematol. 2021 Feb;100(2):437-443. doi: 10.1007/s00277-020-04384-w. Epub 2021 
      Jan 3.